Neonatal sepsis is the most common cause of morbidity and mortality during the neonatal period. Neonatal sepsis is classified as either early‐onset sepsis (EOS; ≤7 days after birth) or late‐onset sepsis (LOS; >7 days after birth). Advances in obstetric and neonatal care have decreased the incidence of neonatal sepsis, especially EOS. Currently, the incidence of group B Streptococcus‐specific EOS has declined to 0.3–0.4 cases/1,000 live births, and overall the EOS incidence has declined to 0.8–1.0 cases/1,000 live births. Nevertheless, EOS remains a severe life‐threatening disease with a mortality rate ranging from 1.5% in term infants to almost 40% in very low‐birthweight infants. Early diagnosis and treatment of neonatal sepsis are important to prevent severe complications. In this era of multi‐resistant microorganisms, however, it is also important to avoid the unnecessary use of antibiotics in sepsis‐negative infants. On the basis of the Centers for Disease Control and Prevention 2010 guidelines, Escobar et al. reported that, in a cohort of 7,004 infants, 13% of both well‐appearing and ill‐appearing infants were evaluated for EOS, and 11% were treated empirically with antibiotics, although only 0.04% of the cohort had blood culture‐confirmed infection. Concern has arisen regarding the EOS results and the empirical antibiotic treatment of hundreds
Pediatrics International – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera